Zai Lab And argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China
- First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China
- Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study